Immunicon's colorectal cancer study meets primary, secondary endpoints

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Immunicon Corp. said its pivotal multi-center clinical trial of 481 patients met its primary and secondary endpoints in metastatic colorectal cancer using the company's CellTrack technology to measure circulating tumor cells.

The primary endpoint was that the number of circulating tumor cells measured three to five weeks after the start of therapy would agree with imaging results six to 12 weeks after therapy began.

For the secondary endpoint, the number of circulating tumor cells prior to and after the start of therapy would predict the clinical end points of progression-free survival and overall survival.

Immunicon, located in Huntingdon Valley, Pa., develops proprietary cell- and molecular-based human diagnostic and life science research products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.